Skip to main content
. 2012 Aug 27;120(15):3069–3079. doi: 10.1182/blood-2012-01-403493

Figure 1.

Figure 1

Fluvastatin prevents glycosylation of FLT3 and impedes receptor maturation. (A) BaF3 FLT3/ITD cells were treated with increasing concentrations of fluvastatin for 24 hours. Lysates were immunoprecipitated with anti-FLT3 antibody and resolved by SDS-PAGE and then probed with FLT3 or 4G10 antiphosphotyrosine antibodies. Quantitation of the upper and lower FLT3 bands is shown in the graph. (B) Cells were treated with 1μM fluvastatin for the indicated time points and analyzed for FLT3 expression as described. Quantitation of the upper and lower FLT3 bands is shown in the graph. (C) The effect of increasing fluvastatin concentration treatment for up to 24 hours on the FLT3-expressing cell lines HB1119, Molm-14, and SEMK-2 cells. In the bottom panel, wild-type FLT3-expressing BaF3 cells were treated ± 1μM fluvastatin for 24 hours followed by ± stimulation with 20 ng/mL FLT3 ligand for 5 minutes. (D) BaF3 FLT3/ITD cells were treated with 1μM fluvastatin for 24 hours after which immunoprecipitated FLT3/ITD was digested with endoglycosidase H for 1 hour. Results are typical of at least 3 independent experiments.